Acta Pharmaceutica Sinica B Volume 10, Issue 8 publishes

October 20, 2020

The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association, Acta Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences -- including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.

Featured papers in this issue are:

ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression by authors Meng Yuan, Xiaobing Chen, Yitang Sun, Li Jiang, Zhongni Xia, Kaixiong Ye, Hong Jiang, Bo Yang, Meidan Ying, Ji Cao and Qiaojun He
(https://doi.org/10.1016/j.apsb.2020.03.008). In this paper, the authors describe how ZDHHC12-mediated S-palmitoylation promotes the cell membrane localization of CLDN3 and maintains its stability in ovarian cancer cells, contributing to the oncoprotein function of CLDN3. When knocking down ZDHHC12, CLDN3 was insufficiently S-palmitoylated leading to the intracellular distribution and the preference to degradation, which inhibited tumor growth.

Novel opioid-neurotensin-based hybrid peptide with spinal long-lasting antinociceptive activity and a propensity to delay tolerance development by authors Karolina Fr?czek, Mattia Ferraiolo, Emmanuel Hermans, Magdalena Bujalska-Zadrozny et al.
(https://doi.org/10.1016/j.apsb.2020.04.014). The authors investigated the behavioral responses exerted by spinal administration of the opioid-neurotensin hybrid peptide, PK23 in adult male rats. The results suggest the potential use of hybrid compounds encompassing both opioid and neurotensin structural fragments in pain management highlighting the potential of synthetic neurotensin analogues as promising future analgesics.

Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein by authors Yuying Zhua, Liuqing Yanga, Jiazhen Xua, Xiyan Yang et al.
(https://doi.org/10.1016/j.apsb.2020.02.007). The authors elucidated the anti-tumor effect and new mechanism of the clinical drug eltrombopag, where eltrombopag exhibited antiangiogenesis effect through targeting HuR in cancer cells and macrophages. The efficiency of HuR inhibitors for tumor inhibition, especially angiogenesis inhibition, suggests that development of new anti-cancer drugs can be based on the molecular structure of eltrombopag.

Other articles published in the issue include:

Review articles

Gene therapy for neurodegenerative disorders: advances, insights and prospects
Wei Chen, Yang Hu, Dianwen Ju
https://doi.org/10.1016/j.apsb.2020.01.015

Conditional reprogramming: next generation cell culture
Xiaoxiao Wu, Shengpeng Wang, Mingxing Li, Jing Li et al.
https://doi.org/10.1016/j.apsb.2020.01.011

Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development
Yixin Sun, Dongyang Zhao, Gang Wang, Yang Wang et al.
https://doi.org/10.1016/j.apsb.2020.01.004

Original articles

Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis
Xiaowei Zhang, Ping Zhang, Lin An, Ningyuan Sun et al.
https://doi.org/10.1016/j.apsb.2020.06.015

Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy
Yuqin Yao, Zhuowei Liu, Manyu Zhao, Zhengxia Chen et al.
https://doi.org/10.1016/j.apsb.2020.04.002

Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors
Zhenzhen Liu, Taoqian Zhao, Zhonghua Li, Kai Sun et al.
https://doi.org/10.1016/j.apsb.2019.12.008

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma
Biao Wang, Fu Peng, Wei Huang, Jin Zhou et al.
https://doi.org/10.1016/j.apsb.2019.12.013

Limitation standard of toxic aconitines in Aconitum proprietary Chinese medicines using on-line extraction electrospray ionization mass spectrometry
Zi-Dong Qiu, Xu-Ya Wei, Rui-Qi Sun, Jin-Long Chen et al.
https://doi.org/10.1016/j.apsb.2019.12.009

Intracellular codelivery of anti-inflammatory drug and anti-miR 155 to treat inflammatory disease
Chao Teng, Chenshi Lin, Feifei Huang, Xuyang Xing et al.
https://doi.org/10.1016/j.apsb.2020.06.005

Doxorubicin-loaded bacterial outer-membrane vesicles exert enhanced anti-tumor efficacy in non-small-cell lung cancer
Kudelaidi Kuerban, Xiwen Gao, Hui Zhang, Jiayang Liu et al.
https://doi.org/10.1016/j.apsb.2020.02.002

A magnetism/laser-auxiliary cascaded drug delivery to pulmonary carcinoma
Jialiang Lin, Qingqing Yin, Binlong Chen, Haoran Zhang et al.
https://doi.org/10.1016/j.apsb.2019.12.017

Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer
Yu Zhou, Wenxi Zhou, Xinli Chen, Qingbing Wang et al.
https://doi.org/10.1016/j.apsb.2019.11.013

Comparative study of mucoadhesive and mucus-penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein
Wujun Dong, Jun Ye, Junzhuo Zhou, Weijue Wang et al.
https://doi.org/10.1016/j.apsb.2019.10.002
-end-
For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/

Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board

APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).

Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).

CiteScore: 10.5
Impact Factor: 7.097
5-Year Impact Factor: 7.865
Source Normalized Impact per Paper (SNIP): 2.210
SCImago Journal Rank (SJR): 1.792

ISSN 2211-3835

Compuscript Ltd

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.